876461-55-1

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-Amino-1-Cbz-piperidine is used as an intermediate in the production of pharmaceuticals such as velpatasvir, an antiviral medication used to treat chronic hepatitis C. Its chiral nature makes it a valuable component in the synthesis of other chiral compounds, contributing to the development of innovative drugs.
Used in Organic Chemistry Research:
(S)-3-Amino-1-Cbz-piperidine is utilized in the study of organic chemistry, providing insights into the properties and reactions of chiral compounds. Its unique structure allows researchers to explore various chemical transformations and mechanisms.
Used as a Reagent in Organic Synthesis:
(S)-3-Amino-1-Cbz-piperidine serves as a reagent in organic synthesis, enabling the creation of a wide range of chemical compounds. Its versatility and selectivity make it a valuable tool for chemists in various applications, from the synthesis of complex molecules to the development of new synthetic routes.

Upstream product

• 216854-23-8 tert-butyl (S)-piperidin-3-yl-carbamate 
• 501-53-1 benzyl chloroformate 
• 876379-22-5 benzyl (3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carboxylate 

Relevant academic research and scientific papers

BENZAMIDE DERIVATIVE

The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

QUINAZOLINEDIONE DERIVATIVE

The present invention relates to quinazolinedione derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

Discovery of aminopiperidine-based Smac mimetics as IAP antagonists

A series of structurally unique Smac mimetics that act as antagonists of inhibitor of apoptosis proteins (IAPs) has been discovered. While most previously described Smac mimetics contain the proline ring (or a similar cyclic motif) found in Smac, a key feature of the compounds described herein is that this ring has been removed. Despite this, compounds in this series potently bind to cIAP1 and elicit the expected phenotype of cIAP1 inhibition in cancer cells. Marked selectivity for cIAP1 over XIAP is observed for these compounds, which is attributed to a slight difference in the binding groove between the two proteins and the resulting steric interactions with the inhibitors. XIAP binding can be improved by constraining the inhibitor so that these unfavorable steric interactions are minimized.